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Chapter 7
General discussion and future perspectives
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In this thesis, we employ Drosophila melanogaster as a tool to uncover fundamental as well as clinically 
relevant aspects of childhood-onset movement disorders PKAN and NS-PME. The nature of these 
diseases precludes extensive research in the patient population, as the groups of patients are small and 
the tissue primarily affected, the brain, is not available for investigation. 
Of models and man
As described in the introduction, the study of these diseases involves disease models in order to eventually 
improve clinical care. The choice of model, however, is far from straightforward and is dictated by 
requirements that follow from the question at hand. For some questions, cellular models may suffice, and 
it may be preferred to use human cells rather than bacterial or yeast cells. Although it is possible to induce 
a genetic defect in immortalized human cells in culture, a novel technique gaining popularity employs 
cells derived from a patient which are subsequently transformed into a cell type of choice, This technique 
makes it possible to retain the original genetic makeup of the patient: these are induced pluripotent stem 
cells, or iPSCs. Vast progress is made in this field of induced pluripotency and subsequent differentiation 
into a tissue of choice (such as neurons) with the exact genetic aberration as is present in the patient. 
However, even this highly sophisticated approach comes with drawbacks. First of all, this method does 
not yield a complete organ (like a brain), and is unable to show functional consequences of a genetic 
defect on a multicellular level. As a consequence, it disregards how different cells, of either shared or 
different lineages, influence each other; a factor of major importance, as shown by the work done with 
NS-PME (Chapter 6 of this thesis). Secondly, these models are unable to represent the more complex 
phenotypes observed in patients, and render it difficult to interpret the results. For example, neuronal 
dysfunction (rather than degeneration) is difficult to assess in a cellular model, whereas it is evident from 
behaviour in a complete organism.
An organism that is often used to study human disease is the mouse. Although attractive models in 
terms of potential complex phenotypes and evolutionary kinship, the two diseases singled out in this 
thesis do not benefit from murine models at the moment of writing. For NS-PME, no mouse model 
has been reported: however, as part of a large phenotype library, a GOSR2 knockout mouse was shown 
to be embryonal lethal1. The heterozygous knockout mouse reportedly shows gait abnormalities1, but 
these have not yet been characterized in more detail. These findings may reflect that the loss of function 
conferred by the homozygous G144W mutation common in patients is indeed only partial. For PKAN, a 
mouse model yielded disappointing results, as the knockout failed to reproduce either iron accumulation, 
neurodegeneration or movement disorders2. Only when challenged by pantothenate deprivation3 or a 
ketogenic diet4 do PANK2-knockout mice show a neurological phenotype: it remains uncertain to which 
extent alterations found in these models correlate with pathophysiological changes occurring in patients.
The merits of Drosophila melanogaster in neuroscientific research
As demonstrated in the experimental chapters of this thesis, Drosophila melanogaster can also be used 
to study these diseases. As a model for neurological disease, in particular genetic disease, it provides an 




phenotypes; and on the other hand, the ease to manipulate molecular processes centrally or peripherally 
located in the pathophysiology of disease (Chapter 2 of this thesis). In addition, Drosophila models are very 
suitable for larger-scale screens of disease-modifying genes or pharmacological compounds. Although 
these studies have inherent merit, these results can then also be transferred to more complex and in 
some cases more representative (but less screenable) models. The non-hypothesis-driven, but rather 
hypothesis-generating nature of these screens enables truly novel insights, which benefit fundamental 
knowledge and clinical implementation alike.
The case of PKAN illustrates this well. After the Drosophila model for PKAN was established, it was 
swiftly employed to find chemical compounds, such as pantethine, capable of replenishing CoA in the 
absence of pantothenate kinase orthologue fumble (fbl)5. These findings were later replicated in other 
models of PKAN4,6. Since pantethine is known to be highly unstable when administered to patients orally 
or intravenously7, we aimed to find compounds other than pantethine to replenish CoA levels in PKAN 
patients in Chapter 3 and Chapter 4.
Coenzyme A-related therapeutics in pantothenate kinase-associated neurodegeneration
A first approach to synthesize a pantethine derivative aimed at improved cellular delivery was 
unsuccessful (Chapter 3 of this thesis). The rationale behind the derivatisation, which involved a moiety 
referred to as 4-thiobutyl triphenylphosphonium (TBTP), was twofold: primarily, we hypothesized that 
the negative charge of the moiety would improve cellular and mitochondrial uptake of the compound 
(and the connected pantetheine) by means of the Nernst effect as reported previously8. In addition, 
the introduction of the large TBTP-group could theoretically improve the compound’s stability, as 
electrochemical and steric hindrance by TBTP could make the active site of pantetheinases less accessible 
to TBTP-pantetheine. By simultaneously improving serum stability and cellular uptake we aimed to 
increase the cellular delivery of the compound, and as such the clinical utility of the compound. However, 
this derivatisation was unable to improve serum stability: this was in line with findings for other, smaller 
moieties introduced on the cysteamine side of pantetheine9. 
Subsequently, the Drosophila model was used to probe the clinically relevant possibility of using 
substrates other than pantethine to synthesize CoA in the absence of pantothenate kinase (Chapter 4 
of this thesis). 4’-phosphopantetheine, a naturally occurring intermediate in the biosynthesis of CoA, was 
shown to be taken up by cells, after which it is converted into CoA. As such, it is able to rescue phenotypes 
caused by CoA deprivation. Also, as 4’-phosphopantetheine is modified on the pantothenate portion 
of pantetheine, it is stable in serum, in contrast to TBTP-pantetheine, making it an attractive option as a 
PKAN therapeutic. 
It has been proposed that such a therapeutic strategy may lead to excess cellular CoA with potentially 
detrimental effects10. However, it should be stressed that this prediction is based on findings in mice 
with genetic deregulation of CoA biosynthesis by overexpression of PANK2. This makes it impossible to 
determine whether the phenotypes observed are the direct consequence of elevated CoA levels as is 
suggested; effects of PANK2 overexpression may extend beyond an increase in Coenzyme A levels alone. 
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PANK2 may have other functions in addition to CoA biosynthesis, and by overexpressing PANK2 CoA 
precursors may accumulate in a toxic manner. Whether supraphysiological CoA concentrations can be 
induced by exogenous administration of CoA biosynthesis substrate in humans, and whether this indeed 
confers detrimental effects in patients, cannot reliably be concluded; and indeed, this should not deter 
the pursuit of this therapeutic strategy.
In parallel, other approaches have been taken to replenish CoA in the brain in the absence of pantothenate 
kinase: examples include RE-02411, a commercially developed derivative of phosphopantothenate, and 
more recently pantazines12. Whereas RE-024 aims to bypass PANK in the production of CoA by supplying 
readily phosphorylated pantothenate11, the mechanism of pantazines relies on allosteric activation of 
PANK312. Both these compounds are non-naturally occurring substances. RE-024 is currently being tested 
in phase III clinical trials and its effectivity is not yet clear. When fed to mice or rats, orally administered 
RE-024 did not reach the bloodstream or the brain11, and the compound was only detected in mouse 
brain after intraventricular injection; however, in monkey blood as well as brain, RE-024 was detectable 
upon oral administration11. This quixotic pharmacokinetic profile makes common toxicology studies 
difficult to carry out. The working mechanism of pantazines relies on stimulation of PANK3, in order to 
increase the production of cytosolic phosphopantothenate and consequently CoA. This compound 
shows attractive pharmacokinetic behaviour and elevates CoA levels in both liver and brain tissue of a 
Pank1/Pank2 double knockout mouse. However, permeation of the compound in brain in vivo is not 
shown, enabling the possibility that the pantazines work by increasing circulating 4’-phosphopantetheine 
produced in the liver. If true, this would make them mechanistically equivalent to direct administration of 
4’-phosphopantetheine, with the additional disadvantages of off-target toxicity and reduced control over 
the amount of 4’-phosphopantetheine produced.
Pathophysiology of pantothenate kinase-associated neurodegeneration
The pathophysiology of PKAN has remained elusive since its first description by Hallervorden and Spatz 
in 192213. Although damaging mutations in PANK2 have been identified as the root cause for the disease, 
the exact mechanism and the pathophysiological importance of the observed iron accumulation have 
remained a mystery. The discovery of CoPAN, an NBIA strongly resembling PKAN caused by mutations 
in the final CoA biosynthesis enzymes14, firmly established the causal role of CoA in this particular type 
of neurodegeneration, yet the downstream pathways that connect CoA to the neuronal demise are 
unknown.
In Chapter 5 we focus on precisely those downstream pathways. Discouragingly, CoA partakes in an 
overwhelming number of cellular reactions; however, in the vast majority of those, CoA is recycled 
rather than consumed. Fascinatingly, in fibroblasts of two CoPAN patients the total amount of CoA was 
no different from control fibroblasts, in spite of an 80% decrease in CoA biosynthesis14. Therefore, we 
focused our attention on those reactions that actively consume CoA instead of those recycling it. Since 
4’-phosphopantetheinylation is the only known CoA-consuming process known thus far** and 
**  One may consider the degradation of CoA by Nudix hydrolases an exception to this statement, but since this does not 




mitochondria appear to be the most strongly affected organelle in PKAN models, this search converged 
on mitochondrial acyl carrier protein (mtACP), which requires a 4’-phosphopantetheine moiety to 
function. In cellular models, both insect-derived and mammalian, 4’-phosphopantetheinylation of mtACP 
reacts strongly to loss of CoA. In addition, it shows a particular sensitivity to loss of PANK2 in human 
neuroblastoma cells, which are relevant in the context of PKAN as a neurodegenerative disease.
Mitochondrial acyl carrier protein in health and disease
The cellular importance of mtACP has been established previously. It was first identified in Neurospora 
crassa as a 4-phosphopantetheinylated mitochondrial protein15 with similarity to the Escherichia coli 
cytosolic acyl carrier protein before its recognition as part of the respiratory chain complex I16. These 
findings were later recapitulated for bovine mtACP17. Another function of mtACP was demonstrated in 
Saccharomyces cerevisiae (baker’s yeast), as it was shown that deletion of mtACP caused a loss of lipoic 
acid (LA)18. In human cells, mtACP was shown to be a short-lived mitochondrial protein (half life <24h)19, 
the downregulation of which rapidly compromises cellular health and decreases both lipoylation and 
complex I function19. Recently, a third function of mtACP was demonstrated:  it fulfils a pivotal role in 
mitochondrial iron handling and iron-sulfur cluster formation20. This function, like the synthesis of LA, 
is 4’-phosphopantetheinylation-dependent, as it is impaired both by mutation of the modified serine 
residue of mtACP, as well as by deletion of the phosphopantetheinyltransferase responsible for this 
modification20. It was recently shown by crystallography that acyl-mtACP stabilises the hydrophobic core 
of ISD11, one of the main components of the iron sulfur cluster biosynthesis machinery21. 
There is evidence to suggest that the crucial function of mtACP is not its role in complex I. mtACP has 
been encountered as a free matrix protein in several organisms22–24. In Yarrowia lipolytica, mutation of 
the mtACP 4’-phosphopantetheine-carrying serine residue mimics the loss of the complete protein and 
confers lethality25. Interestingly, loss of the complex I subunit nb4m leads to complete dissociation of 
mtACP from complex I, yet this strain is viable26, indicating that the essential function of mtACP is separate 
from its role in complex I and oxidative phosphorylation26. Furthermore, S. cerevisiae lacking mtACP suffers 
from defective respiration18, which was ascribed to defective synthesis of LA since unlike in many other 
species, yeast complex I is a separate protein that operates without an acyl carrier protein18. Furthermore, 
after treatment with chloramphenicol to inhibit mitochondrial translation in human cell culture, intact 
complex I was undetectable; nevertheless, unbound mtACP was retained and even more abundant than 
in control cells, in contrast to many other components of Complex I27. This indicates that mtACP fulfils 
another, vital role besides its participation in Complex I: this may be the synthesis of LA. 
In contrast to its physiological functions, the role of mtACP in human disease is relatively unknown. 
Mutations in mtACP (or, as it is known in humans, NDUFAB1) have been actively searched in children with 
unexplained Complex I deficiency 28–30, but no mutations have been found. We demonstrated that loss of 
mtACP has devastating consequences in Drosophila. Ubiquitous knockdown of mtACP is incompatible 
with life, glial knockdown confers mostly late pupal lethality and neuronal knockdown leads to progressive 
impairment of locomotion and early death (unpublished data). In Chapter 5, we show that loss of mtACP 
in the Drosophila wing leads to severely abnormal morphology , similar in pattern 
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to what was observed upon disruption of CoA biosynthesis. In the experiments done, knockdown of 
mtACP induces much stronger phenotypes than knockdown of the CoA biosynthesis enzymes; this may 
reflect the relative strengths of the respective RNAi constructs, or it could indicate that reduction of CoA 
biosynthesis does not cause an equal reduction of mtACP 4’-phosphopantetheinylation. In agreement 
with the earlier conclusion in this chapter that the vital function of mtACP is not its function in complex I, 
we found that overexpression of UAS-NDI1, the single-subunit yeast complex I, was unable to rescue the 
wing phenotype caused by CoA biosynthesis defects (data not shown). Recalling the question at the start 
of this paragraph, one may well wonder what the symptomatology of a mtACP/NDUFAB1 mutation would 
be. Given the findings in Chapter 5, such a defect may be either incompatible with life or, when the loss of 
mtACP function would be relatively minor, could give rise to an NBIA-like phenotype.
mtACP and downstream factors in PKAN/CoPan
CoA biosynthesis defects share clinical features with the recently discovered disorder MePAN, which is 
caused by mutations in mitochondrial trans-2-enoyl-CoA reductase (MECR) and leads to a lipoylation 
defect31: an important difference between these diseases is iron accumulation. Given the similarity 
between these diseases, the function hampered by loss of 4’-phosphopantetheinylation of mtACP leading 
to neurodegeneration will most likely be the production of LA. The observation that the CoA biosynthesis 
defects feature neurodegeneration with brain iron accumulation, and MePAN features neurodegeneration 
without iron accumulation is in line with the findings in Chapter 5. Due to CoA biosynthesis defects, 
mtACP is not adequately 4’-phosphopantetheinylated, and therefore impaired in both iron handling and 
LA biosynthesis, leading to iron dyshomeostasis as well as neurodegeneration. Secondary to mutations 
in MECR, LA production is compromised, yet mtACP is 4’-phosphopantetheinylated and can still function 
in iron-sulfur cluster biogenesis, thus ensuring proper iron handling. Although the fate of iron in mtACP 
mutants has not yet been determined by us or by others, the defect in iron sulfur cluster biosynthesis 
resulting from loss of mtACP is thought to be biochemically similar to deficiency of frataxin, where 
mitochondrial iron accumulation is evident32.
If this explanation of iron accumulation is correct, deferiprone treatment will not prevent 
neurodegeneration from occurring in PKAN and CoPAN; even if it corrects the iron handling defect, it 
will fail to rescue the lipoylation defect. In other words, it would suggest that iron accumulation is an 
epiphenomenon which occurs in parallel to disruption of lipoylation. This latter process is sufficient to 
cause neurodegeneration, as proven by the neurodegenerative nature of MePAN. However, it cannot be 
excluded that the accumulated iron adds insult to injury by accelerating damage to the globus pallidus, 
e.g. by oxidative stress. The results of the deferiprone trial in PKAN will be able to demonstrate to separate 
these primary and secondary effects. 
The observation that fibroblasts of MePAN patients demonstrate prominent hypolipoylation31, in the 
absence of any extracerebral symptomatology, further argues for the specific vulnerability of the globus 
pallidus to disruption of the lipoylation pathway in humans. A mouse model of MePAN also displays 
neurodegeneration, most notably Purkinje cell loss33. Interestingly, knockdown of malonyl CoA-acyl 




kickstarting the synthesis of LA) was shown to exert pleiotropic effects in mice, with a much stronger 
emphasis on systemic mitochondrial dysfunction34; unfortunately, the brain of these mice was not 
studied. Two mechanisms could underlie this discrepancy. Due to the blocking of malonyl transfer from 
CoA to mtACP, CoA may be “trapped” in the form of malonyl-CoA, rendering recycling of the CoA moiety 
impossible and leading to a secondary CoA deficiency with extracerebral effects. Also, malonyl-CoA 
inhibits fatty acid oxidation, which may also add to the energy disequilibrium seen in tissues other than 
brain in MCAT-deficient mice.  
Lipoylation defects in turn induce loss of activity of lipoylation-dependent enzymes, such as the E2-
subunits of pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (αKGDH) and branched-
chain α-ketoacid dehydrogenase (BCKDH)31,35,36. PDH-E2-deficiency forms a rare cause of PDH-
deficiency37,38, which phenocopies the neurodegenerative phenotype of defects in MECR and CoA 
biosynthesis. Based on this observation, dysfunction of PDH-E2 may be the final common pathway for 
these three diseases, consistent with our result described in Chapter 5. In Chapter 5 we show that cells 
treated with HoPan show reduced PDH-activity. Furthermore, we prove the intricate causal relationship 
between PDH and deleterious phenotypes of CoA deprivation in vivo by pharmacological and genetic 
modulation of PDH. However, we did not investigate the activity and phenotypic contribution of the 
other two lipoylation-dependent α-ketoacid dehydrogenases αKGDH and BCKDH, or the lipoylation-
dependent glycine cleavage protein H. Dysfunction of these proteins could contribute to the phenotype 
of PKAN patients. In patient tissue, there is histopathological evidence of accumulation of ubiquitinated 
proteins and neuroaxonal spheroids39: this may be caused by αKGDH dysfunction, since loss of αKGDH 
leads to activation of mTORC1 and suppression of autophagy40. 
Old data in a new light
The pathophysiological model for PKAN and related disorders proposed in Chapter 5 enables a more 
thorough comparison between molecular findings in PKAN and that of isolated defects along the 
proposed CoA–mtACP–lipoic acid–PDH-axis. A summary of the above is given in Figure 1.
The consequences of mtACP loss on cellular metabolism have recently been investigated in human HeLa41 
cells; levels of amino acids and select fatty acids have been measured in mtACP knockout Arabidopsis 
plants earlier42. It is intriguing to compare these data with the results of metabolomics analysis of PKAN 
patient blood samples43. However, it is important to keep in mind that in the blood samples metabolites 
were measured in a derivative of the extracellular space, whereas the studies in HeLa cells and Arabidopsis 
record intracellular metabolic changes. In addition, many of the changes in the peripheral blood of 
patients did not reach statistical significance, most likely due to the small number of patients included. In 
all three systems elevated glycine levels were found41–43, which can be explained by insufficient lipoylation 
of the glycine cleavage system. In addition, both in HeLa cells and blood samples of PKAN patients, 
glutamate levels are elevated and glutamine levels are reduced41,43. Reduced levels of isoleucine, leucine 
and valine, all substrates of BCKDH, are found both in blood samples of patients and HeLa cells41,43: it 
remains unclear why these substrates would be less abundant, since loss of BCKDH activity would cause 
elevated concentrations of the enzyme’s substrates. All three studies report alterations in the cellular lipid 
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profiles41–43: however, in order to truly compare the alterations in lipid profiles between cells with CoA 
biosynthesis defects and cells with mitochondrial fatty acid synthesis defects, a side-by-side comparison 
is necessary.
Another biochemical landscape that can be probed and compared is that of iron-sulfur clusters (ISC). 
Studies in PKAN patient fibroblasts44 and iPSC neurons45 have demonstrated reduced activity of the 
enzyme aconitase in spite of normal aconitase protein levels. Since aconitase needs an ISC in order to be 
enzymatically active, this decrease in activity has been ascribed to an ISC shortage secondary to an iron 
handling defect44,45. Similarly, a loss of aconitase activity was seen upon induction of mtACP pathology20. 
Knockout of mtACP, site-directed mutagenesis of its 4’-phosphopantetheinylation site or knockout of 
the phosphopantetheinyltransferase enzyme all induced this loss of aconitase phenotype in yeast20. In 
contrast, knockout of lipoic acid synthase left aconitase activities unchanged, excluding a contribution 
from mitochondrial fatty acid synthesis to the ISC phenotype. 
A previous observation in Drosophila models of CoA deprivation was hypoacetylation of proteins, which 
was ascribed to lower levels of cytosolic acetyl-CoA46. The source of cytosolic acetyl-CoA used for this 


























A summary of the proposed pathyphysiological model based on the ndings in 
this thesis. On the left side of the image, crucial pathyphysiological elements in
the axis spanning coenzyme A, mtACP, lipoylation and PDH-E2 are shown. On the
right side of the image, pathology of these processes is shown, corresponding to
their physiological counterparts on the left.
Figure 1
A summary of the proposed pathophysiological model based n the finding  in this thesis. On the left side of the image, crucial 
pathophysiological elements in the axis spanning coenzyme A, mtACP, lipoylation and PDH-E2 are shown. On the right side of the 




deficiency could explain the hypoacetylation phenotype observed as well as the resulting increase in 
genomic instability49, by a mechanism similar to what is described for Drosophila mutants in mitochondrial 
citrate transporter scheggia (sea)50. It was also shown that HDAC inhibition ameliorated the phenotype 
of fbl flies46, which implied a causal role of hypoacetylation in the Drosophila phenotype. However, in 
models for Huntington’s disease, the beneficial effect of HDAC inhibition was recently ascribed to 
stimulation of PDH51. Thus, previously reported hypoacetylation phenotypes in PKAN models may have 
been a reflection of loss of PDH activity, and efforts to reverse this hypoacetylation may have stimulated 
PDH explaining their efficacy. 
Novel pathophysiological insights, novel therapeutics?
If the results of Chapter 5 can be translated to PKAN/CoPan/MePAN patients, this would suggest that 
treatment aimed at stimulating PDH may prove beneficial. Dichloroacetate (DCA) stimulates PDH 
by inhibiting pyruvate dehydrogenase kinase (PDK). Although its effect on pyruvate metabolism was 
reported earlier52, strong evidence for its biochemical efficacy in patients has been around for more than 
30 years53,54. The molecule is able to cross the blood-brain barrier55,56, lowers CSF/brain lactate 57,58, can be 
administered orally 54,59 and shows relatively mild adverse effects54,59 even after long-term use60. However, 
the effects of DCA on clinical outcomes have been disappointing54,59. In a large randomized controlled trial 
aimed at paediatric patients with congenital lactic acidosis, treatment with DCA did not elicit a beneficial 
effect on neurological outcome59. Important to mention is that of all 43 patients enrolled in the study, 
only 11 had a PDH deficiency; 25 had respiratory chain defects and the remaining 7 had a mitochondrial 
deletion syndrome59. With many patients in the study suffering from defects downstream of PDH, the lack 
of clinical efficacy in this population may have been caused by improper patient selection and lack of 
homogeneity, rather than lack of clinical effectiveness of DCA.
Although DCA showed positive effects in Drosophila flies with CoA biosynthesis defects (Chapter 5), its 
target (PDK) inhibits the E1-subunit of the PDH complex, which is upstream of the lipoylated E2-subunit of 
PDH. Since knockdown of PDK also proved beneficial, the influence of PDK is apparently strong enough 
to overcome defects in another subunit in the PDH complex.  Phenyl butyrate, another clinically used 
drug, was found to exert effects similar to dichloroacetate61, i.e. inhibition of PDH-E1 phosphorylation: 
interestingly, it also showed efficacy in a cell line derived from a patient suffering from PDH-E2 deficiency 
62. This, in combination with the beneficial effects observed in Drosophila, justifies further exploration of 
DCA or phenyl butyrate as a therapeutic approach in PKAN. These may well be combined with the CoA-
based therapies discussed earlier in this chapter.
Given the findings in Chapter 5, pharmacological inhibition of SIRT4 would be another therapeutic 
strategy in PKAN/CoPAN/MePAN since by genetic knockdown of SIRT4, phenotypes secondary to CoA 
biosynthesis defects were ameliorated. SIRT4 inhibitors have not been developed, and their clinical use 
will be limited due to the role of SIRT4 as both a tumour suppressor as an oncogene depending on the 
tissue 63. Also, a recent study in Drosophila demonstrated that knockout of SIRT4 was detrimental to 
lifespan and energy metabolism64. Therefore, with the information available at the moment of writing, 
inhibition of SIRT4 is most likely not a suitable therapeutic strategy.  
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Administration of LA may appear to be a more targeted, inexpensive therapeutic approach. Lipoic 
acid is used as a food supplement and is well-tolerated65, also when given for longer periods of time66. 
However, a study using HeLa cells showed that exogenous lipoic acid does not influence the lipoylation 
of mitochondrial proteins when NDUFAB1 is knocked down19, making it an unlikely therapeutic in PKAN/
CoPAN/MePAN.
In summary, the findings of Chapter 4 and 5 suggest that treatment of PKAN patients with 
4’-phosphopantetheine may be successful; in addition, stimulation of the downstream target PDH with 
DCA may further support the globus pallidus neurons. The combination of these strategies may decrease 
the necessary dose of 4’-phosphopantetheine, which is as of yet untested in humans and carries a yet 
unclarified possible risk of toxicity67. Supplementation of lipoic acid may not be beneficial, based on the 
pharmacodynamics of the compound in cell culture. 
New insights in North Sea Progressive Myoclonus Epilepsy
In this thesis, the experience with Drosophila models of neurological illness is extended to a disease 
other than PKAN: North Sea Progressive Myoclonus Epilepsy (NS-PME), caused by mutations in GOSR2. 
Although PKAN and NS-PME are both progressive childhood-onset monogenic movement disorders, 
they differ in several aspects. Whereas PKAN is a neurodegenerative disorder, signs of neurodegeneration 
have not been found in imaging or pathology studies in NS-PME patients68. This likely reflects on a 
fundamentally different pathophysiological basis for the progressive symptomatology.  In addition, while 
PKAN appears to be associated with disturbed cellular metabolism, the known cellular function of GOSR2 
is related to protein transport through the Golgi apparatus69. By which mechanism impairment of this 
function leads to pathology, and which factors mediate it, is currently unclear. However, the answers 
to those questions are of crucial importance in the search of therapeutics for MS-PME. Therefore, a 
model organism reproducing key features of the disease is first required to find these answers, either by 
hypothesis-driven or non-hypothesis-driven research.
Ubiquitous downregulation of membrin, the Drosophila orthologue of GOSR2, leads to a neurological 
phenotype in adult flies (Chapter 6 of this thesis). However, there is late pupal lethality associated with 
its knockdown in all cells as well, in accordance with previous findings70. The neurological phenotype 
is readily recapitulated by glial, but not neuronal knockdown of membrin. Interestingly, none of these 
flies feature late pupal lethality. This suggests an additional, non-CNS pathology, induced by ubiquitous 
membrin knockdown. Given the elevated creatine kinase found in patients71,72 and the recent association 
of GOSR2 with dystroglycanopathy73 this may reflect a concomitant muscle phenotype. When inferring 
the neurological consequences of loss of GOSR2 function, it appears justified to use the CNS-specific 
knockdown of membrin as a model in order to prevent interference from non-CNS pathology on the 
phenotype studied. 
The neurological phenotype observed upon knockdown of membrin is seizure-like behaviour in response 
to heat (Chapter 6 of this thesis). When exposed to an environmental temperature of 40 °C, a proportion 




wings or legs. This heat-induced seizure paradigm has been used before to study mutations conferring 
Dravet syndrome in Drosophila74; here the model was also evaluated electrophysiologically74. In our study, 
we did not characterise our NS-PME Drosophila model electrophysiologically; these details on the exact 
depolarisation and repolarisation behaviour of neurons may shed light on the underlying molecular 
defect that causes this hyperexcitability. To justify the interpretation of this behaviour as epileptic we used 
sodium barbital, a GABA-agonist and anticonvulsant, to demonstrate responsiveness to anticonvulsant 
medication. In addition, the model reflects the progressive nature and heat sensitivity of symptoms also 
seen in patients (Chapter 6 of this thesis).
One of the most intriguing findings in Chapter 6 is the recapitulation of neurological features observed 
upon ubiquitous membrin knockdown by flies with exclusively glial knockdown of membrin. Although 
seizures are a reflection of disturbed neuronal function, it suggests the root cause of this disturbance 
is located in glia; neurons appear insensitive to downregulation of membrin at least with regards to 
seizure-like behaviour. This appears to contradict earlier findings in a Drosophila model for NS-PME, 
which ascribed a crucial function to membrin in neurons70. Upon ubiquitous overexpression of mutant 
membrin constructs in a membrin null background, dendritic growths defects, reduced axonal trafficking 
and NMJ abnormalities were reported70. However, these phenotypes were not assessed with cell-type 
specific expression of the mutant constructs, nor was a rescue of the phenotype sought using cell-type 
specific expression of membrin in the membrin null background. Some or all of the neuronal phenotypes 
described may therefore be secondary to glial loss of membrin, which can readily be studied in the fly 
model described in Chapter 6 of this thesis.
Glia in (models of) epilepsy: a changing paradigm 
Drosophila models demonstrating a glial substrate for seizure-like behaviour in response to mechanical 
stimulation75,76, temperature elevation77,78 or photic stimulation78,79 have been reported previously. 
Processes disrupted in these models include glial calcium homeostasis77, extracellular ionic balance76 and 
membrane maintenance79. Two studies have dissected the responsible glial subtype conferring seizure 
sensitivity, both of which found this to be cortex glia77,79. Similar investigations, aimed at identifying the 
glial subtype responsible for seizures in membrin knockdown may hint at the essential glial function 
disrupted in NS-PME, and this in turn may hold the key to finding the cellular process responsible. 
In humans, glia have been investigated in the context of a different PME: Unverricht-Lundborg disease 
(ULD), caused by mutations in cystatin B80. For ULD a mouse model has been developed which strongly 
resembles ULD in terms of symptomatology81. Interestingly, this mouse model features glial activation82,83, 
which is present before neuronal loss occurs84,85 and is therefore suggested to initiate or exacerbate ULD 
pathophysiology84,85. However, the neurodegenerative nature of this disorder makes it difficult to translate 
these findings to NS-PME, in which neurodegeneration has (at this moment) not been demonstrated by 
postmortem histology or imaging68.    
ULD aside, there is increasing evidence for a glial contribution to some forms of epilepsy86. Three 
mechanisms have been put forward86,87: impaired clearance of potassium ions from the surroundings 
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of the neuron, impaired clearance of excitatory neurotransmitter glutamate and impaired production 
of glutamine for neuronal synthesis of GABA. These mechanisms can be investigated in the Drosophila 
model. Expression of the glutamate sensor (mCD8-)iGluSnFR88 or GABA sensor GABA-Snifit89 may reveal 
disturbances in the concentration of these neurotransmitters. Neuronal knockdown or pharmacological 
inhibition of the glutamate receptor may demonstrate the influence of glutamate signalling on the 
phenotype, and the balance between glutamine and glutamate can be investigated by studying the level 
of glutamine synthase. Given the role of GOSR2/membrin in the Golgi apparatus, another reasonable 
idea is to study the (mis)localisation of glutamate and ion transporters using immunofluorescence in 
Drosophila tissue. Of particular interest is the inwardly rectifying potassium channel, a FLAG-tagged 
version of which90 can be overexpressed in the glia of the NS-PME Drosophila model to investigate 
channel (mis)localisation as well as possible beneficial effects of increased potassium clearance. 
The exact Golgi pathology caused directly by mutations in GOSR2, and which is expected to underlie 
the processes described in the previous paragraph, remains elusive. GOSR2, a Qb-SNARE protein, is 
required for the fusion of ER-derived vesicles with the cis-Golgi 68,70. This fusion involves the formation 
of a complex between a v-SNARE (v for vesicle) and a t-SNARE (t for target); in this fusion, the t-SNARE 
is formed by GOSR2 together with syntaxin-5 and Sec22-b; the v-SNARE is Bet170,91. It has been shown 
that GOSR2 mutations causative of NS-PME lead to a GOSR2 protein featuring a reduced fusion rate with 
Bet170. However, which vesicles are affected, which proteins are contained by these vesicles, and how this 
connects to the eventual defects on the neuronal level remains unknown.
Screening possibilities in NS-PME
Another, possibly complementary strategy to find the underlying molecular mechanism underlying NS-
PME is the use of screens. An advantage of this method would be its non-hypothesis-driven character, 
which enables the discovery of novel and hitherto unrecognized elements in the pathophysiology of NS-
PME, with the possible prospect of therapeutic intervention. Drosophila is an excellent platform for these 
screens, as outlined in Chapter 2. In order to facilitate a genetic modifier screen, a repo-GAL4::membrin 
RNAi recombinant was made, which can be crossed to a library of genetic constructs and screened for 
its seizure sensitivity, which may then be increased or decreased. This approach is able to identify glial 
factors influencing the phenotype, but cannot infer which neuronal processes are involved. To screen 
for neuronal intermediates conferring seizure-like behaviour a more complex setup is required, which 
employs two separate binary systems. In this setup, the the first binary system is used to induce the 
condition in which to screen (e.g. repo-QF>QUAS-membrin RNAi), the second serves to express the 
putative modifier constructs (e.g. nsyb-GAL4). A similar approach was previously used for spinocerebellar 
ataxia type 392. Another option is a compound screen, which assesses the effect of clinically approved 
drugs on the phenotype and may lead to more direct therapeutic consequences.
Although all these screens are technically possible, the current eliciting of the phenotype is laborious, 
hampering the efficacy of any screen. The use of electrophysiological measurements, as discussed 
previously, may provide a more robust parameter as a (first) readout; an alternative is the testing of many 




recording. Another possibility is the search for phenotypes in other, easier to screen organs such as the 
Drosophila eye or the wing; however, this moves away from the epilepsy phenotype, which makes it more 
difficult to (immediately) translate the findings to patients.
Concluding remarks and future outlook
In this thesis, Drosophila proves its value as a versatile and useful model for neurological disorders, 
complementing the scarce but valuable information that can be obtained from patients. Using this 
model, we found a possible therapeutic and proposed a comprehensive pathophysiological mechanism 
(with novel therapeutics as a possible corollary) for PKAN. For NS-PME we gained new and unexpected 
insights as well as a screenable model. For PKAN, investigating whether these findings also hold true in 
patients is the next logical step. In NS-PME, the Drosophila model may provide insights and information 
necessary to devise a future therapy. 
This research begins and ends with patients. Our findings make a step forward towards the treatment of 
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